Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophy
Abstract Facioscapulohumeral muscular dystrophy (FSHD) is a degenerative muscle disease caused by loss of epigenetic silencing and ectopic reactivation of the embryonic double homeobox protein 4 gene (DUX4) in skeletal muscle. The p38 MAP kinase inhibitor losmapimod is currently being tested in FSHD...
Saved in:
| Main Authors: | Rajanikanth Vangipurapu, Jonathan Oliva, Amelia Fox, Francis M. Sverdrup |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-77911-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SIX transcription factors are necessary for the activation of DUX4 expression in facioscapulohumeral muscular dystrophy
by: Amelia Fox, et al.
Published: (2024-12-01) -
Dux Is Dispensable for Skeletal Muscle Regeneration: A Study Inspired by a “Red Flagged” Publication and Editorial Oversight
by: Kenric Chen, et al.
Published: (2025-05-01) -
AAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD
by: S. Sohn, et al.
Published: (2025-09-01) -
Therapeutic Strategy and Clinical Path of Facioscapulohumeral Muscular Dystrophy: Review of the Current Literature
by: Qi Xie, et al.
Published: (2024-09-01) -
Facioscapulohumeral muscular dystrophy: a review of pathogenesis, clinical symptoms, and treatment
by: T. Mikalauskas, et al.
Published: (2023-10-01)